Event Registration
October 28 & 29, 2024, 4:30 PM CET | 3:30 PM (GMT) | 11:30 AM ET (New York)
(Convert this to your time zone)
Conventional preclinical models often fail to accurately evaluate antibody-based therapeutics, forcing drug developers to adopt cautious and complex strategies. JAX's cutting-edge humanized models offer a solution by faithfully reproducing human physiology and pathology. These innovative models enable more accurate predictions of biologic drug candidate performance, providing better and more predictive preclinical PK, efficacy, and safety data.
Join our two-day virtual symposium to explore how JAX's humanized models can revolutionize your antibody-based therapeutic development. Industry experts will showcase our platforms and services, demonstrating their transformative potential at critical moments within the drug development pipeline.
Day 1 will include four 15-20 minute presentations, while Day 2 will feature three sessions of the same duration. More details are listed below.
Join us as we discuss:
This virtual event is complimentary.
No fees will be charged for registering.
|
October 28 |
|
Opening Remarks and Introduction Director, European Corporate and Commercial Development The Jackson Laboratory |
|
New Directions for Therapeutic Antibody Formats: An Overview of Development Trends and the Current Clinical Pipeline Business Intelligence Creator The Antibody Society |
|
Atlas™ Mice Provide a New and Differentiated Toolset for Rapid Generation of Developable Human Therapeutic Antibodies Chief Technology Officer AbTherx |
|
Using the HuPK™ Platform to Predict the PK of Candidate Therapeutic Antibodies Director, Business Development – Europe The Jackson Laboratory |
|
Biology-Guided Engineering of Human Albumin Fusion Proteins: From Cross-Species Studies to Proof-Of-Concept in Transgenic Mouse Models Postdoc in the Laboratory of Adaptive Immunity and Homeostasis University of Oslo and Oslo University Hospital |
|
October 29 |
|
|
Opening Remarks and Introduction Director, European Corporate and Commercial Development The Jackson Laboratory |
|
Next-Generation Immune System Humanized Models for the Development of Immunotherapy Senior Scientific Engagement Manager The Jackson Laboratory |
|
Enhancing T-Cell Bispecific Antibody Therapy: Efficacy and Safety Insights from Humanized Mouse Models PhD candidate in the Discovery Pharmacology Department The Roche Innovation Center, Zürich |
|
Humanized Mice for the Assessment of the Safety of Immunotherapies Principal Scientist - Preclinical The Jackson Laboratory |
|
Presentation Title Presenter Name Presenter Title Presenter Company |
